Clinical TrialApr 23, 2026, 06:01 AM
GLSI-100 Phase III Data Accepted for 2026 ASCO Meeting
AI Summary
Greenwich LifeSciences announced that an abstract for its FLAMINGO-01 Phase III clinical trial has been accepted for publication and poster presentation at the 2026 ASCO Annual Meeting. The presentation on June 1, 2026, will include preliminary injection site reaction immune response data from the non-HLA-A*02 open-label arm. Preliminary analysis of recurrence rates in the fully enrolled 250-patient non-HLA-A*02 arm shows an approximately 70-80% reduction, trending similarly to Phase IIb results.
Key Highlights
- Abstract accepted for 2026 ASCO Annual Meeting, presentation on June 1, 2026.
- Preliminary Phase III data shows 70-80% reduction in recurrence rate.
- Non-HLA-A*02 arm fully enrolled with 250 patients.
- DTH reactions increased by 4x (290%) in non-HLA-A*02 population.
- Immune reactivity increased 100% to 700% across HLA-A types after treatment.
Price Impact
More from GLSI